---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Long-term morbidity"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Long-term morbidity. Topics: Skeletal-related events in patients with bone metastases, Prevention of skeletal-related events with bone-modifying agents, ESMO recommendations on bone metastases and skeletal-related events, Visceral crisis: prognosis, and 9 further topics. 13 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Skeletal-related events in patients with bone metastases

> “BM is associated with accelerated bone resorption leading to increased morbidity due to a range of skeletal-related events (SREs) including bone pain (BP), pathological fracture (PF), spinal cord compression (SCC), tumor-induced hypercalcemia (TIH) and surgery or radiation therapy (RT) to bone”
> “Studies have demonstrated that at least one SRE occurs in nearly 50% of patients with bone metastases of breast cancer”
> “In randomized trials in advanced breast cancer, one of the major SREs occurs on average every 3–6 months after the onset of BM.”

Source: [Zhang et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5832676/)

<a id="topic-2.2.1.7-2"></a>

### Prevention of skeletal-related events with bone-modifying agents

> “Patients with breast cancer who have evidence of bone metastases should be treated with BMAs.”
> “The analgesic effects of BMAs are modest, and they should not be used alone for bone pain.”

Source: [Van Poznak et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/29035643/)

<a id="topic-2.2.1.7-3"></a>

### ESMO recommendations on bone metastases and skeletal-related events

> “A multidisciplinary approach is recommended to manage patients with bone metastases and to prevent skeletal-related events (SREs) [V, A].”
> “Bone-modifying agents (BMAs) such as bisphosphonates or denosumab are recommended for patients with bone metastases, regardless of symptoms [I, A].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="topic-2.2.1.7-4"></a>

### Visceral crisis: prognosis

> “The diagnosis of visceral crisis in metastatic breast cancer is associated with poor prognosis.”
> “Sbitti et al. showed a median Overall Survival (mOS) of 4.7 weeks in a retrospective cohort of 35 patients with hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer and visceral crisis pre-treated with two hormonal therapy lines, of whom 77 % had liver metastases.”
> “Thus, the type of organic involvement in patients with VC is an established prognostic factor, with hepatic involvement being more associated with worse mOS.”

Source: [Andrade et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11112279/)

<a id="topic-2.2.1.7-5"></a>

### Central nervous system metastases: incidence by subtype and line of therapy

> “Among 18 075 patients with MBC, 1102 (6.1%) had at least 1 brain metastasis at first-line therapy initiation.”
> “For the remaining 16 973 patients, cumulative incidence of brain metastases at 60 months was 10% in patients with hormone receptor-positive (HR+)/HER2- disease, 23% for HR+/HER2+ disease, 34% for HR-/HER2+ disease, and 22% for triple-negative breast cancer (TNBC).”
> “Brain metastases incidence increases per line of therapy for every MBC subtype.”

Source: [Sammons et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40163696/)

<a id="topic-2.2.1.7-6"></a>

### Central nervous system metastases: pooled incidence in HR-positive, HER2-negative disease

> “Four studies including 14656 patients reported the incidence of brain metastases specifically in patients with HR+/HER2− MBC.”
> “Pooled cumulative incidence of brain metastases among this subgroup was 0.15 (95% CI: 0.078–0.27), with a median follow-up of 33.0 months (IQR: 31.9–36.2).”

Source: [Kuksis et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8168821/)

<a id="topic-2.2.1.7-7"></a>

### Central nervous system metastases: detection by screening MRI and ABC8 position

> “Data from a non-randomized, prospective screening study in patients with ABC reveal that approximately one-quarter of patients across all subtypes (HR+/HER2-negative, TNBC, and HER2+) who undergo a baseline and 6-month screening MRI will be diagnosed with brain metastases”
> “As we await these data, the existing evidence base, though limited, provides rationale to consider screening in patients at high risk of developing brain metastases and in situations where the knowledge of brain metastases status would impact the choice of systemic therapy.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.1.7-8"></a>

### Central nervous system metastases: rising incidence with longer survival

> “The incidence of brain metastases in breast cancer patients is increasing mainly due to improved systemic therapies resulting in more durable control of extracranial metastatic disease and prolonged survival.”

Source: [Cardoso et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11231614/)

<a id="topic-2.2.1.7-9"></a>

### Disease progression: shorter benefit from endocrine monotherapy after first line

> “Although most HR-positive breast cancers benefit from first-line ET, most eventually become endocrine-resistant.”
> “Second-line ET monotherapy has a median progression-free survival (PFS) of only 2–6 months, compared to 1–4 years for first-line ET”

Source: [Brett et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8365900/)

<a id="topic-2.2.1.7-10"></a>

### Treatment toxicities over sequential lines: assessment beyond adverse event frequency

> “Assessment of treatment-related toxicity should extend beyond the frequency and severity of clinician-reported adverse events.”
> “Rates of treatment discontinuation due to toxicity should be considered alongside patient-reported outcomes (PROs) and validated measures of health-related quality of life, including the specific domains assessed and the completeness of their reporting.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.1.7-11"></a>

### Treatment toxicities over sequential lines: vasomotor symptoms and alopecia

> “Vasomotor symptoms (VMS; also known as hot flashes) are common side effects of endocrine therapy, in particular in young women receiving LHRH analogs.”
> “Alopecia is a common distressing treatment toxicity that negatively impacts body image, quality of life and psycho-social functioning.”
> “However, hair loss may occur with ADCs, CDK4/6 inhibitors and endocrine therapy (male-pattern androgenetic alopecia).”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.1.7-12"></a>

### Treatment toxicities over sequential lines: interstitial lung disease and cognitive impairment

> “In the treatment of breast cancer, ILD has been associated with antibody drug conjugates, mTOR inhibitors, HER-2/EGFR targeted oral tyrosine kinase inhibitors, PD-1 or PD-L1 inhibitors, radiation therapy and rarely, CDK4/6 inhibitors”
> “Cognitive complaints are usually subtle or moderate, and most frequently related to ChT. However, other treatments, such as ET, targeted agents, and immunotherapy may also have an impact in cognitive function”

Source: [Cardoso et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11231614/)

<a id="topic-2.2.1.7-13"></a>

### Treatment toxicities over sequential lines: patient-reported side effects

> “Patients with HR+/HER2- mBC experience substantial disease and treatment-mediated side effects, with low patient-physician concordance associated with worse HRQoL.”
> “The only symptom that worsened in over 10% of the overall cohort was bone pain severity”

Source: [Nsubayi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13748321/)

Additional sources: [Atre et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38816556/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
